The Pre-IPO Perpetual Mirage: What Hyperliquid's SEC Letter Really Reveals

Five IPOP markets have completed their full lifecycles on Hyperliquid. The data shows something striking: the IPO opening price was consistently 10.8% to 38.4% lower than the last IPOP price before listing. That sounds like a testament to accurate price discovery, right? The Hyperliquid Policy Center (HPC) and trading firm trade[XYZ] certainly think so. They sent a joint letter to the SEC on August 19, proposing a regulatory framework for these “Initial Pre-IPO Perpetuals.” But when I read the letter, I don’t see a call for clarity. I see a carefully framed narrative designed to sell the SEC on a product that, beneath the surface, is a synthetic perpetual contract with a fancy name. An IPOP is a perpetual swap that automatically terminates when a company goes public. It allows traders to go long or short on a company’s pre-IPO price, but it grants no equity, no allocation rights, no voting power. It’s a derivative of a derivative—a bet on the price of a bet that hasn’t happened yet. The underlying technology is the same Hyperliquid order book that powers every other perp on the platform. The innovation is not in the code; it’s in the product lifecycle and the regulatory narrative. The HPC letter itself acknowledges five key areas: regulatory classification, disclosure, listing standards, market integrity, and investor access. These are standard talking points for any derivative market. But the letter omits the most crucial detail: how is the settlement price determined? Is it the IPO issuance price, the first-day closing price, or some other oracle? Without that, the entire price discovery claim is built on sand. During the 2017 ICO mania, I audited a multi-sig contract that looked flawless until I found 12 logic flaws. The same instinct kicks in here. The 5 IPOP markets are a tiny sample. The data is provided by a stakeholder—trade[XYZ]—that likely acts as the market maker and liquidity provider on these products. That’s not independent verification; it’s self-reported marketing. The 10.8-38.4% discount could just as easily reflect a manipulated pre-IPO price or a lack of liquidity, not efficiency. In fact, a large discount suggests the IPOP market was overpricing the company before listing, which is exactly the kind of speculation that regulators fear. The HPC is trying to frame this as a public good—improving IPO pricing efficiency—but it’s really a bid to legitimize a speculative tool that currently operates outside any clear regulatory framework. Follow the fear, not the chart. The fear here is that the SEC’s silence on this letter could be interpreted as implicit approval. It isn’t. The SEC has not responded. The HPC is trying to pre-empt regulation by offering a narrative that makes IPOPs look like a natural extension of capital markets. But the Howey test is ambiguous. Are IPOPs securities? They are contracts that derive value from the performance of an underlying security (the IPO company). They involve an investment of money, in a common enterprise (the Hyperliquid platform), with an expectation of profit from the efforts of others (the company’s performance, but also the market maker’s actions). That’s a high-risk classification. The letter acknowledges this by asking for a clear regulatory classification, but it doesn’t propose specific safeguards—no KYC, no audit trail, no oracle transparency. That’s a red flag. If you can design a market that genuinely improves price discovery, you should also be able to design a transparent settlement mechanism. The HPC hasn’t done that. The product is a synthetic perpetual, and the only innovation is the termination event. That’s not enough to warrant a regulatory carve-out. What’s more, the 5 completed IPOPs are all for companies that already went public. The data is backward-looking and selective. We don’t see the failed markets, the ones where liquidity dried up, or where the settlement price was contested. The architecture of trust is not built by letters alone. The contrarian truth is that the HPC’s letter is a sign of weakness, not strength. Hyperliquid is a successful DEX, but it faces a ceiling: it can’t grow its user base beyond crypto natives without regulatory clarity. So it’s trying to pull the SEC into a conversation on its own terms. But the SEC is not a startup accelerator. It will ask hard questions about insider trading, since pre-IPO information asymmetry is extreme. It will ask about market manipulation, since the same entity trade[XYZ] is likely providing liquidity on both sides of the book. And it will ask about investor protection, since the IPOP contracts are offered to retail traders without any disclosure of the settlement mechanism. I see the potential: a world where pre-IPO price discovery is decentralized and continuous, reducing the IPO discount problem. But that potential is being sold on a promise of data that is not independently verified. My experience in 2020, when I watched friends lose everything in Compound’s governance token crash, taught me that the human cost of opaque financial products is real. The IPOP product is a derivative on a future event, and the only thing that makes it special is the termination. That’s not enough to justify applauding the regulatory push. Takeaway: The HPC letter is a clever policy move, but it doesn’t change the underlying technical and ethical questions. Before we celebrate, we need to see the settlement oracle, the audit reports, and the liquidity data. If you can’t trust the data, you can’t trust the price. And if you can’t trust the price, the entire edifice is just a speculative casino with a SEC letterhead.